The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
- 13 December 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 22 (4), 740-747
- https://doi.org/10.1038/sj.leu.2405049
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseasesApplied Microbiology and Biotechnology, 2007
- Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell GrowthOnline Journal of Public Health Informatics, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisThe New England Journal of Medicine, 2007
- Histone deacetylase inhibitors prevent exocytosis of interleukin-1β-containing secretory lysosomes: role of microtubulesBlood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and TreatmentMayo Clinic Proceedings, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Chronic Myeloproliferative DisordersHematology, 2003
- Flow cytometric analysis of live cell proliferation and phenotype in populations with low viabilityCytometry, 1999